JPRN-UMIN000024669
Completed
未知
The phase I/II study of the adjuvant therapy using alpha-galactosylceramide pulsed dendritic cells for patients with advanced high-grade salivary gland tumor followed by standard therpies. - The phase I/II study of the adjuvant therapy using alpha-GalCer pulsed DCs for salivary gland tumor.
ConditionsSalivary gland tumor
Overview
- Phase
- 未知
- Intervention
- Not specified
- Conditions
- Salivary gland tumor
- Sponsor
- Chiba University Hospital
- Enrollment
- 6
- Status
- Completed
- Last Updated
- 2 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- Not provided
Exclusion Criteria
- •1\) Past history of hepatitis. 2\) A positive response for HBs antigen/HCV antibody/HIV antibody/HTL\-V1 antibody. 3\) Concurrent corticosteroid therapy. 4\) Pregnancy or lactation. 5\) Autoimmune disease. 6\) Sever infection 7\) Uncontrolled DM. 8\) Sever pulmonary emphysema or fibrosis. 9\) Serious cardiac disease. 10\) Double cancer. 11\) Hypersensitivity for albumin 12\) Judgement of physician.
Outcomes
Primary Outcomes
Not specified
Similar Trials
Completed
Phase 1
The phase I/II study of the adjuvant therapy using alpha-galactosylceramide pulsed antigen presenting cells for patients with high-grade salivary grand tumor followed by standard therpies.High-grade salivary grand tumorJPRN-UMIN000011509Department of Otorynolaryngology, Head and Neck Surgery, Graduate School of Medicine, Chiba University9
Active, not recruiting
Phase 1
eoadjuvant Lu-PSMA radioligand therapy and Ipilimumab in men with very high-risk prostate cancer (NEPI)Patients with very high-risk prostate cancer (as defined by a total Gleason-Score =4+4 [ISUP-GG 4+5] and clinical stage cT3 (digital rectal examinations or imaging based) plus clinical nodal status cN+ or Serum-PSA level > 20 ng/ml who are candidates for radical prostatectomy with pelvic lymph node dissection.Therapeutic area: Diseases [C] - Male Urogenital Diseases [C12]CTIS2024-514386-19-00niversitaetsklinikum Essen AöR58
Recruiting
Not Applicable
A Phase I/II Trial of combined adjuvant therapy with gemcitabine and cisplatin for resected biliary tract cancerResected biliary tract cancerJPRN-UMIN000004359Shinshu University School of Medicine, Surgery33
Completed
Phase 2
Efficacy and Safety study of adjuvant therapy with capecitabine plus oxaliplatin (XELOX) for the Japanese patient with Stage III curative resection Colon cancer -Phase II studyColon cancerJPRN-UMIN000006742Multicenter Study Group of Osaka (MCSGO), Colorectal Cancer Treatment Group195
Active, not recruiting
Not Applicable
Phase II trial assessing neoadjuvant therapy with FEC 100 followed by Taxotere® (docetaxel) plus Vectibix® (panitumumab) in patients with operable, HR and Her-2 negative breast cancer. TVA study. - TVA studyRH- and Her2- operable breast cancer, in neoadjuvant situationMedDRA version: 9.1Level: LLTClassification code 10022882Term: Invasive ductal breast cancerEUCTR2009-012853-39-FRCentre Jean Perrin